NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Roche's Ventana ALK (D5F3) CDx to identify best responders to Novartis' non-small cell lung cancer drug Zykadia (ceritinib).
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.